Atelerix at ELRIG Drug Discovery 2025: Enabling the Future of Cell Research
The Atelerix team were delighted to take part in ELRIG Drug Discovery 2025, held at the ACC in Liverpool on
Atelerix signs agreement with CliniSciences to broaden access to cryo-free preservation solutions across Europe and North Africa
Agreement with specialist life science and diagnostic labs distributor expands global operational reach and market penetration New distribution channels to
Atelerix and Rodon Global partner to integrate cryo-free preservation technology into specialist logistics solutions
Initial agreement to incorporate Atelerix’s non-cryogenic cell preservation technology into international freight and logistics services for drug discovery and clinical
Overcoming Organoid Preservation Challenges in CRO Workflows
Abstract Contract Research Organisations (CROs) are increasingly adopting organoid models for drug discovery, toxicology, and preclinical testing. These three-dimensional cellular
From Lab to Market: Recent Advances and Commercialisation of Organoid Technologies
By Sophie Reay Organoids are three-dimensional (3D) tissue cultures derived from stem cells that self-organise into structures that closely
Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion
Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion Industry-leaders Sunil Shah (CEO, o2h
Mini Organs, Major Impact: How Organoids Are Redefining Drug Development & Personalised Medicine
By Sophie Reay Organoids are miniature, three-dimensional (3D) tissue cultures that mimic the structure and function of specific organs. They
Grant Writing That Stands Out: How Ambient Cell Preservation Can Strengthen Your Application
Securing research funding is a competitive process. Review panels look for more than just sound science – they’re also seeking
Rise in the use of organoids to replace animal models: the issue with storage and shipment
By Sophie Reay, Historically, preclinical testing on animal models formed a critical step in the drug discovery and development pipeline,
Transforming mRNA Vaccine Distribution: How Atelerix’s CytoStor™ Could Eliminate the Need for the Ultracold Chain
As the global biotechnology sector works to extend the reach of life-saving mRNA vaccines, a persistent challenge remains: the carbon-intensive,
Two Years On: Stem Cell Therapy Brings Sustained Vision Improvement Thanks to Alginate-Based Delivery
At Atelerix, we’re proud to support pioneering work that translates innovative science into real-world patient impact. A recent clinical milestone
Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic preservation technology eliminates
